期刊
BIOMEDICAL CHROMATOGRAPHY
卷 29, 期 12, 页码 1842-1848出版社
WILEY
DOI: 10.1002/bmc.3505
关键词
UPLC-MS; catalpol; acteoside; Rehmannia glutinosa extract; chronic kidney disease; pharmacokinetic study
类别
资金
- National Basic Research Program of China (973 Program) [2011CB505300, 2011CB505303]
- Nature Science Foundation of China [81072996, 81102743]
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization [ZDXM-1-10]
- Construction Project for Jiangsu Key Laboratory for High Technology of TCM Formulae Research [BM2010576]
In this study, a sensitive and robust ultra-performance liquid chromatography-mass spectrometry method with multiple-reaction monitoring mode was developed, validated, and applied to determine pharmacokinetics of catalpol and acteoside in normal and doxorubicin-induced chronic kidney disease rats after oral administration of Rehmannia glutinosa extract. The lower limits of quantification for catalpol and acteoside in rat plasma were 2.62 and 0.61 ng/mL, with a signal-to-noise ratio of 10. Precision and accuracy studies showed that catalpol and acteoside plasma concentrations were within the 10% range in all studies. The extraction recoveries of catalpol and acteoside were both >68.24% and the matrix effects ranged from 96.59 to 101.62%. The method was successfully applied to the pharmacokinetic study of catalpol and acteoside after oral administration of RG extract to normal and model rats, respectively. This study might further support the traditional use of RG to treat kidney diseases clinically. Copyright (c) 2015 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据